Related Experiment Video
Updated: Sep 1, 2025
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
2.9K
ADCY5-related dyskinesia: a case report.
Shih-Ying Chen1, Chen-Jui Ho1, Yan-Ting Lu1
1Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Niaosung District, 123 Dapi Road, Kaohsiung, 83301, Taiwan.
Neurological Research and Practice
|August 14, 2022
Summary
Adenylyl cyclase 5 (ADCY5) related dyskinesia is a rare movement disorder. This report details the first diagnosed patient in Taiwan with this condition, highlighting its key features.
Area of Science:
- Neurogenetics
- Movement Disorders
Background:
- Adenylyl cyclase 5 (ADCY5) related dyskinesia is a rare neurological disorder.
- Characterized by early-onset choreoathetosis, dystonia, and myoclonus, primarily affecting limbs, face, and neck.
Discussion:
- The condition presents with axial hypotonia and episodic dyskinesia exacerbations.
- Both sporadic and inherited forms exist, with autosomal dominant inheritance being predominant.
Key Insights:
- This study reports the first case of ADCY5-related dyskinesia identified in Taiwan.
- The case presentation contributes to understanding the geographic distribution and clinical spectrum of ADCY5 disorders.
Outlook:
- Further research is needed to explore genetic variations and therapeutic strategies for ADCY5-related dyskinesia.
- Increased awareness and diagnosis in diverse populations can improve patient outcomes.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
363
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
363
01:15Parkinson's Disease: Overview
686
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
686
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
570
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
570
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
840
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
840
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
426
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
426
01:20Gastrointestinal Motility Disorders
573
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
573